| Objective:Essential hypertension has the highest incidence in cardiovascular disease, both clinical and experimental data show that there are individual differences of drug effective in hypertensive patients on antihypertensive therapy,even for the same drug. Renin angiotensin system plays an important role at the occurrence and development of essential hypertension.Angiotensin converting enzyme inhibitor,ACEI and angiotensinⅡtype 1 receptor antagonist,AT1RA has become the first choice of treatment to clinicians.This article intends to explore relationship between the gene polymorphism of ACE,angiotensinogen(AGT),and AT1R in Chinese Han nationality patients with essential hypertension to the therapeutic efficacy of the irbesartanMethods:To examine whether the response to the angiotensinⅡreceptor antagonist irbesartan varies depending on the ACE,AGT,AT1R genotype,we prospectively studied the effect of irbesartan in 118 hypertensive patients.After a 2-week observation period,irbesartan was administered at 75 mg/day and blood pressure was measured every 2 to 4 weeks for 8 weeks.All the patients' blood sample were collected and the genotypes of ACE,AGT,AT1R were detected.And the relationship between the gene polymorphism of ACE,AGT,and AT1R to the therapeutic efficacy of the irbesartan was explored.Results:The therapeutic efficacy of irbesartan among different ACE genotypes (χ2=5.303,P = 0.258 ),but the decline of DBP between different genotypes show significantly difference(P<0.05).The therapeutic efficacy of irbesartan among different AGT genotypes(χ2=9.671,p = 0.046) shows some difference,the decline in the value of SBP between genotypes were significantly different(P <0.05).The therapeutic efficacy of irbesartan among different AT1R genotypes(χ2=6.327,P = 0.182) shows no significant difference,neither do the decline of BP after therapy.Conclusion:The antihypertensive efficacy of irbesartan is associated with the ACE gene polymorphism to some extent.So do the AGT genotypes.But the antihypertensive effect of irbesartan in patients has no relationship with the AT1R genotypes. |